Search

Displaying results 681 - 690 of 5449 in total
  1. Drug

    Thimerosal

    go.drugbank.com/drugs/DB11590
    Approved

    Although thimerosal is banned in several countries, it continues to be included as a preservative in some vaccines in the United States and many vaccines in the developing world [L1685].

  2. Drug

    Rilpivirine

    go.drugbank.com/drugs/DB08864
    ApprovedInvestigational

    [A31328] It is a diarylpyrimidine derivative. … [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's

    Mixtures: ODEFSEY 200 MG/25 MG/25 MG FİLM KAPLI TABLET, 90 ADET, ODEFSEY 200 MG/25 MG/25 MG FİLM KAPLI TABLET, 30 ADETSynonyms: 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
  3. Drug

    Rozibafusp Alfa

    go.drugbank.com/drugs/DB19233
    Investigational

    Rozibafusp Alfa is under investigation in clinical trial NCT04058028 (Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)).

  4. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers. … It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]

    Categories: Rearranged during Transfection (RET) Inhibitors
  5. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg). … Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose

  6. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. The standard therapy for systemic lupus ery...

    Products: Saphnelo 300 mg/2 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 1 ADET
  7. Drug

    Magnesium carbonate

    go.drugbank.com/drugs/DB09481
    Approved

    Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].

    Mixtures: Calcium Et Magnesium Tab, Sintra-ES
  8. Drug

    Acetylcysteine

    go.drugbank.com/drugs/DB06151
    ApprovedInvestigational

    Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results. Ac...

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSIONProducts: ACETILCISTEINA EG, FLUIQ®600 MG
  9. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a combination of a low dose of the steroid prednisolone, 3mg, and amoxapine.

  10. Drug

    Pertuzumab

    go.drugbank.com/drugs/DB06366
    ApprovedInvestigational

    It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. … It was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer.

    Mixtures: PHESGO® 1200 MG/600 MG, PHESGO® 1200 MG/600 MGProducts: PHESGO SOLUTION FOR SUBCUTANEOUS INJECTION 600 MG/600 MG / 10 ML, PHESGO SOLUTION FOR SUBCUTANEOUS INJECTION 1200 MG/600 MG / 15 ML